Demand for Wegovy and other GLP-1 drugs used to treat obesity and diabetes has skyrocketed, but a new report suggests that many people may not be sticking with their weight-loss treatment long enough.

Dr. Joseph Moleski of STL Med Weight Loss reveals a cutting-edge, affordable telemedicine approach using GLP-1 treatments.

A majority of people with overweight or obesity prescribed glucagon-like peptide 1 receptor agonists (GLP-1 RAs) discontinue them within 1 year, with higher quit rates among those without type 2 ...

More than 1 in 8 American adults are using GLP-1’s for weight loss. Experts say these are the nutritional gaps and side effects that should not to be overlooked.

“GLP-1 helped me enhance everything that I was already doing — eating healthy and working out,” the tennis champion tells PEOPLE Serena Williams reveals to PEOPLE that she’s been using a GLP-1 ...

Share on Pinterest An increasing number of people without diabetes are using GLP-1 agonist drugs for weight loss only. Image credit: MarkHatfield/Getty Images. The last few years have seen a marked ...

The use of drugs like Ozempic, Wegovy and Zepbound in people with type 1 diabetes has risen sharply over the past decade, a new study finds, even though there’s little information on the drugs’ safety ...

One-to-one meetings erupted in the struggle to avoid the once-a-year performance review meeting and have a (hopefully) meaningful conversation more often. The problem is most 1:1 meetings are a waste ...